{
  "source": "PA-Notification-Vecamyl.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1131-11\nProgram Prior Authorization/Notification\nMedication Vecamyl® (mecamylamine)\nP&T Approval Date 5/2014, 5/2015, 3/2016, 4/2017, 5/2018, 6/2019, 6/2020, 7/2021,\n9/2022, 10/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nVecamyl (mecamylamine) is indicated for the management of moderately severe to severe\nessential hypertension and uncomplicated cases of malignant hypertension.1 Vecamyl was\noriginally approved under the brand name Inversine, which was launched in the 1950s. The\nproduct was withdrawn in September 2009; withdrawal was not due to safety concerns. As of\nMarch 2013, the FDA issued an approval for mecamylamine to be re-marketed in the United\nStates.2\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Vecamyl will be approved based on one of the following criteria:\na. Diagnosis of moderately severe to severe essential hypertension\n-OR-\nb. Diagnosis of uncomplicated malignant hypertension\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Vecamyl will be approved based on the following criterion:\na. Documentation of a positive clinical response to Vecamyl therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Vecamyl [package insert]. New York, NJ: Vyera Pharmaceuitcals LLC; July 2018.\n2. U.S. Food and Drug Administration website.\nwww.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overv",
    "References:\n1. Vecamyl [package insert]. New York, NJ: Vyera Pharmaceuitcals LLC; July 2018.\n2. U.S. Food and Drug Administration website.\nwww.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204054.\nAccessed September 6, 2024.\nProgram Prior Authorization/Notification - Vecamyl\nChange Control\n5/2014 New Program\n5/2015 Annual review. No changes.\n3/2016 Annual review with administrative changes.\n4/2017 Annual review. Updated references.\n5/2018 Annual review with administrative changes.\n6/2019 Annual review. Updated references.\n6/2020 Annual review. Added reference for mecamylamine history.\n7/2021 Annual review. Updated references.\n9/2022 Annual review. Added state mandate footnote.\n10/2023 Annual review. Updated references.\n10/2024 Annual review. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}